Suggested remit: To appraise the clinical and cost effectiveness of Beremagene geperpavec within its marketing authorisation for treating skin wounds assocatied with dystrophic epidermolysis bullosa.
Status Awaiting development
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information The topic routing was discussed at the Topic Selection Oversight Panel (TSOP) in April 2023. The panel concluded that the topic was suitable for a Technology Appraisal. Please see project documents for further details
Process STA Standard
ID number 3959

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
31 October 2023 Following a routing challenge raised by the company, regarding the Topic Selection Oversight Panel (TSOP) decision to route Beremagene Geperpavec as a Technology Appraisal, the start of this evaluation is delayed. The timelines for the evaluation will be confirmed once TSOP have reviewed the challenge.
14 June 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
14 June 2023 Topic selection
14 June 2023 Topic selection. Routing update
19 January 2023 (14:00) Scoping workshop
09 November 2022 - 07 December 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
20 May 2022 In progress. Scoping commencing

For further information on our processes and methods, please see our CHTE processes and methods manual